bThe conventional hemagglutinin (HA)-and neuraminidase (NA)-based influenza vaccines need to be updated most years and are ineffective if the glycoprotein HA of the vaccine strains is a mismatch with that of the epidemic strain. Universal vaccines targeting conserved viral components might provide cross-protection and thus complement and improve conventional vaccines. In this study, we generated DNA plasmids and recombinant vaccinia viruses expressing the conserved proteins nucleoprotein (NP), polymerase basic 1 (PB1), and matrix 1 (M1) from influenza virus strain A/Beijing/30/95 (H3N2). BALB/c mice were immunized intramuscularly with a single vaccine based on NP, PB1, or M1 alone or a combination vaccine based on all three antigens and were then challenged with lethal doses of the heterologous influenza virus strain A/PR/8/34 (H1N1). Vaccines based on NP, PB1, and M1 provided complete or partial protection against challenge with 1.7 50% lethal dose (LD 50 ) of PR8 in mice. Of the three antigens, NP-based vaccines induced protection against 5 LD 50 and 10 LD 50 and thus exhibited the greatest protective effect. Universal influenza vaccines based on the combination of NP, PB1, and M1 induced a strong immune response and thus might be an alternative approach to addressing future influenza virus pandemics.T he conventional influenza vaccines that are available currently to prevent seasonal flu outbreaks depend mainly on the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) (1, 2). However, HA-and NA-based conventional influenza vaccines sometimes fail to prevent flu epidemics because the HA and/or NA in the vaccine strains is a mismatch with that in circulating virus strains (3-7). Universal influenza vaccines (UIVs) that induce effective and long-term cross-protection and address the risk of mismatch may overcome the shortcomings of conventional influenza vaccines. Therefore, the development of a UIV capable of inducing long-term immunity and cross-protection remains a priority in influenza vaccine research (8).Influenza viruses are classified as type A, B, or C based on their nucleoprotein (NP) and matrix protein (M). Among the three subtypes, influenza A virus has been the target of UIVs, because the diverse influenza A strains frequently trigger influenza epidemics and pandemics. A previous study indicated that humans mount a good response to the highly conserved internal proteins NP, M1, and polymerase basic 1 (PB1) of influenza A virus (9); therefore, these highly conserved influenza A virus antigens are the basis of UIVs. Multiple studies have investigated the potential of NP (10-13), matrix protein 1 (M1) (14-17), and ion channel (M2, mainly M2e) (18-27) as alternative vaccine antigens for the prevention of seasonal and pandemic flu outbreaks. PB1 has also shown protective potential but requires further investigation for inclusion in UIVs. Košík et al. (28) constructed a DNA vaccine based on PB1, which provided some protective immunity in a mouse model. We previously constructed DNA vaccines ...
Urgent demands of assessing respiratory disease transmission in airliner cabins had awakened from the COVID-19 pandemics. This study numerically investigated the cough flow and its time-dependent jet-effects on the transport characteristics of respiratory-induced contaminants in passengers' local environments. Transient simulations were conducted in a three-row Boeing 737 cabin section, while respiratory contaminants (2 μm–1000 μm) were released by different passengers with and without coughing and were tracked by the Lagrangian approach. Outcomes revealed significant influences of cough-jets on passengers' local airflow field by breaking up the ascending passenger thermal plumes and inducing several local airflow recirculation in the front of passengers. Cough flow could be locked in the local environments (i.e. near and intermediate fields) of passengers. Results from comparative studies also revealed significant increases of residence times (up to 50%) and extended travel distances of contaminants up to 200 μm after considering cough flow, whereas contaminants travel displacements still remained similar. This was indicating more severe contaminate suspensions in passengers’ local environments. The cough-jets was found having long and effective impacts on contaminants transport up to 4 s, which was 8 times longer than the duration of cough and contaminants release process (0.5 s). Also, comparing to the ventilated flow, cough flow had considerable impacts to a much wider size range of contaminants (up to 200 μm) due to its strong jet-effects.
With airborne transmissions found as one of the major transmission routes of SARS-CoV-2, its transmission in airliner cabin environments drew special attention due to high number of imported cases and in-cabin transmissions. This study numerically investigated the transmission of COVID-19 by cough-induced particles in a cabin section of Boeing 737 model. One passenger was coughing in each case, while cough particles with measured size distributions were released during coughs and were tracked using the Lagrangian framework. Outcomes revealed that cough flow released by passengers could develop rapidly into a strong turbulent cough jet, breaking up the local airflow field. The released cough particles were largely dominated by the cough jet within 5 s, especially the first 1.5 s. Deposition of particles under 100 µm were relatively delayed when released from a window-seat location. Small particles (under 50 µm) released by a window-seat passenger were more likely to spread widely in the studied cabin section, which could lead to the highest exposure risks to nearby passengers. Also, due to ventilation design and seating arrangement, cough particles released by the middle-seat passenger were found easily trapped in his/her own local environment. Cough particles released from aisle-seat passengers had the least exposure risk to adjacent passengers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.